| scholarly article | Q13442814 |
| P2093 | author name string | Allan DeCamp | |
| Marc Gurwith | |||
| Peter Gilbert | |||
| Huyen Cao | |||
| Norman G Jones | |||
| Michael L Peterson | |||
| P2860 | cites work | Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 |
| Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus | Q28302762 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa | Q35849596 | ||
| Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. | Q35867686 | ||
| Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. | Q36368095 | ||
| HIV-1 vaccine development: progress and prospects | Q36718578 | ||
| HIV/AIDS vaccines: 2007. | Q36986517 | ||
| Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy | Q38877655 | ||
| HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis | Q38879959 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells | Q40211599 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. | Q44368205 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 | ||
| AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope | Q47289180 | ||
| Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. | Q51186094 | ||
| HIV-1 T-cell vaccines: evaluating the next step | Q64376882 | ||
| Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination | Q73097737 | ||
| AIDS research. Did Merck's failed HIV vaccine cause harm? | Q79843419 | ||
| AIDS research. Promising AIDS vaccine's failure leaves field reeling | Q81398375 | ||
| HIV vaccines | Q82900063 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunization | Q1415366 |
| P304 | page(s) | 1136-1140 | |
| P577 | publication date | 2008-12-09 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection | |
| P478 | volume | 27 |
| Q27302081 | A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen |
| Q28077096 | Adult immunization-Need of the hour |
| Q36050577 | Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets |
| Q36305326 | Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination |
| Q47093684 | Conserved HIV Epitopes for an Effective HIV Vaccine |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q35709133 | Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine |
| Q40332276 | Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial |
| Q34450043 | Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study |
| Q35043547 | Is developing an HIV-1 vaccine possible? |
| Q36957775 | Mucosal immunology of HIV infection |
| Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
| Q33527383 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine |
| Q37785947 | Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV |
| Q42230293 | Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q37466832 | The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis |
| Q35540033 | Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties |
Search more.